PHARMACY

NCPA to FDA: Rescheduling hydrocodone combo products to create headache for legitimate pain patients

BY Michael Johnsen

ALEXANDRIA, Va. — The National Community Pharmacists Association on Monday submitted comments to the Food and Drug Administration urging the agency to preserve access to hydrocodone-containing pain relief products, as FDA considers moving the medications from the Drug Enforcement Administration’s Schedule III list of controlled substances to the more restrictive Schedule II list.

“NCPA understands the concerns about diversion and abuse of these products and shares these concerns,” stated Ronna Hauser, NCPA VP policy and regulatory affairs. “Nevertheless, moving all of these hydrocodone products to Schedule II will result in significant barriers for patients who have a legitimate need for these products and it will result in adding to the nation’s health care costs with no assurance of a reduction in diversion and abuse.”

NCPA advised the proposed change would create an inordinate amount of hurdles in prescribing the prescription-strength pain reliever such as preventing prescribers from phoning in prescriptions to pharmacies, stopping prescription refills, limiting who can prescribe, and in some instances, prohibiting electronic prescribing. NCPA also suggested that rescheduling would likely increase the value of illicit hydrocodone products, which may prompt more crimes against pharmacies.

NCPA identified for the FDA a range of alternative solutions to reduce drug abuse without the harm to patients that rescheduling hydrocodone would cause. These included more effective education of prescribers, linking their DEA registration to such training; prescription drug monitoring databases and programs; shutting down rogue pain clinics; offering more disposal options for excess medications; greater use of electronic prescribing; and more scrutiny of controlled substances delivered by mail order pharmacies.


Find us on Facebook for more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Nebraska medication-management research study gets NACDS Foundation grant

BY Alaric DeArment

ARLINGTON, Va. — A university research project to look at the potential effects on patient health of incorporating medication management strategies into existing care teams has won a grant from the National Association of Chain Drug Stores’ philanthropic arm.

The NACDS Foundation said it gave the University of Nebraska Medical Center one of three research grants for the project, which will look at the effects of the strategies when they’re incorporated into teams such as medical homes and accountable care organizations.

"Coordinated patient-centered models are promising forums to drive quality and improve patient outcomes while also reducing public health costs," NACDS Foundation president Kathleen Jaeger said. "The primary medical intervention for most patients is medication therapy. Thus, by incorporating medication management strategies into emerging care models, we hope to optimize therapies and evaluate patient outcomes. We are pleased to award this research grant to the University of Nebraska Medical Center in alliance with Blue Cross and Blue Shield of Nebraska, their medical homes and community pharmacy Walgreen Co."

The research will focus on patients with high blood pressure and Type 2 diabetes from around Nebraska during a two-year period, using the Nebraska Health Information Initiative, a statewide bilateral information sharing portal that will allow physicians and pharmacists to share data across clinical settings.

"This research seeks to improve the health and wellness of Nebraskans by better coordinating care between pharmacists and physicians," lead researcher, chairman of the Innovation in Community Pharmacy Practice Network and University of Nebraska Medical Center professor Donald Klepser said. "Research shows that when pharmacists and physicians team up, better care is delivered at lower cost. We believe this project will lead to major improvements in the way care is delivered in communities throughout the state."


 

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Katz Group Canada appoints Sharon Driscoll as EVP, CFO

BY Alaric DeArment

MISSISSAUGA, Ontario — The company that operates Canada’s Rexall and Rexall Pharma Plus retail pharmacy chains has hired on a former Sears Canada executive.

Katz Group Canada announced Monday the appointment of Sharon Driscoll as EVP and CFO.

Driscoll previously served as SVP finance and CFO for Sears Canada and has worked in financial leadership positions in retail for more than 25 years. Before Sears, she worked in several senior-level positions at Loblaw Cos. Ltd., including SVP corporate development. Driscoll is a chartered accountant and graduated with honors from Queen’s University.

"Sharon’s more than two decades of retail leadership experience will make her a tremendous addition to the Rexall management team," Katz Group Canada CEO Frank Scorpiniti said. "Throughout her career, Sharon has demonstrated a capacity to identify strategic growth opportunities as well as the ability to achieve efficiencies, and we are excited to have her continue that record of success as a member of our team."


Find us on Facebook for more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?